A Randomised, Placebo-controlled Trial Of Oxpentifylline Versus Placebo In The Treatment Of Erythropoietin-resistant Anaemia In Chronic Kidney Disease
Funder
National Health and Medical Research Council
Funding Amount
$345,189.00
Summary
Anaemia in chronic kidney disease (CKD) is linked to poor health outcomes, increased death rates and high health care costs. Drugs that stimulate red blood cell production are routinely used to treat CKD patients with anaemia, however some patients do not respond to these drugs. The HERO trial is a clinical trial designed to test the safety, effectiveness and cost benefits of a drug Oxypentifylline, in treating CKD patients with anaemia that is unresponsive to red blood cell stimulating treatmen ....Anaemia in chronic kidney disease (CKD) is linked to poor health outcomes, increased death rates and high health care costs. Drugs that stimulate red blood cell production are routinely used to treat CKD patients with anaemia, however some patients do not respond to these drugs. The HERO trial is a clinical trial designed to test the safety, effectiveness and cost benefits of a drug Oxypentifylline, in treating CKD patients with anaemia that is unresponsive to red blood cell stimulating treatments.Read moreRead less